About the Study: IMPACT-2 Part B

For adults living with symptoms associated with Post Traumatic Stress Disorder (PTSD)

The goal of this study is to evaluate the safety and efficacy of four doses of methylone, at three different dose levels for participants living with PTSD. Each dose is separated by one week. This study is sponsored by Transcend Therapeutics.

Length of Study:  28 day screening period. 4 weeks open-label treatment period: (3 dosing days, spaced out 1 dose per week). 8 weeks follow-up period.
Total length: Approximately 13 weeks

Eligibility 

You may be eligible to participate in this study if you:

• are between the ages of 18-70 years old
• meet DSM-5 criteria for Post Traumatic Stress Disorder (PTSD) diagnosis
• have failed at least one treatment for PTSD (either psychotherapy or pharmacological treatment)
• are willing to refrain from taking any psychiatric medications or interventions during the study.

If chosen for this study, you will be compensated for every study visit that you complete, and we can provide transportation if needed. 

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.